NVS : Summary for Novartis AG Common Stock - Yahoo Finance

U.S. Markets open in 1 hr 6 mins

Novartis AG (NVS)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
68.17+0.42 (+0.62%)
At close: 4:02 PM EST

68.57 0.40 (0.59%)
Pre-Market: 8:03 AM EST

People also watch:
GSKSNYAZNLLYABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close67.75
Open67.66
Bid68.60 x 9000
Ask68.67 x 100
Day's Range67.57 - 68.30
52 Week Range67.28 - 88.49
Volume2,478,667
Avg. Volume2,724,706
Market Cap169.31B
Beta0.71
PE Ratio (TTM)24.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.72 (3.99%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com1 hour ago

    Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

    Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.

  • Reutersyesterday

    Novartis CEO plays down prospects for Actelion bid: Blick

    Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: "We have always said that we will concentrate on complementary acquisitions in the range of $2 billion to $5 billion." He did not elaborate. Actelion is worth nearly $20 billion at Friday's closing price.

  • Reutersyesterday

    Novartis says 82 pct of leukemia patients in remission after CAR-T

    An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday. Interim results from the multi-center trial for 50 patients with acute lymphoblastic leukemia whose cancer returned or did not respond to other treatment, showed that 41 were disease-free three months after treatment with the drug, called CTL019. Novartis estimated that 60 percent of those responders were relapse-free after six months.